Alfacalcidol Tablets

This product is rapidly converted into 1alpha;, 25-dihydroxyvitamin VtD3 by the liver, which regulates the balance of calcium and phosphorus in the body, increases intestinal absorption of calcium and phosphorus, promotes bone mineralization, reduces plasma parathyroid hormone levels, reduces bone calcium elimination, relieves bone and muscle pain, and improves intestinal calcium malabsorption associated with osteoporosis caused by menopause, aging and the use of glucocorticoids.

The main ingredient is alfacalcidol.

This product is white tablets.

1. Rickets and osteomalacia. 2. Renal osteodystrophy. 3. Osteoporosis. 4. Hypoparathyroidism.

0.5μgqd.

Long-term and high-volume use may cause anorexia, nausea, vomiting, abdominal distension, diarrhea, constipation, stomach pain, headache, dizziness, insomnia, excitement, memory loss, increased urea nitrogen, creatinine, and urine calcium, increased GOT, GPT, LDH, and alpha-GTP, itching, rash, and conjunctival congestion.

Patients with hypercalcemia. Calcium supplements should be taken as appropriate while taking this product. Closely monitor blood calcium and urine calcium levels during medication, adjust the dosage, and stop the drug immediately if hypercalcemia occurs. After the blood calcium value returns to the normal range, the drug can be re-administered at a reduced dose.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

1 Calcium agents: Combination with calcium agents may cause elevated blood calcium, so blood calcium should be monitored. 2 Thiazide diuretics: This type of diuretic can promote the kidney's absorption of calcium, and there is a risk of hypercalcemia when used together. 3 Digitalis glycosides: Hypercalcemia in patients taking digitalis drugs can easily induce arrhythmias. If this drug is used in combination, blood calcium should be closely monitored. 4 Barbiturates, anticonvulsants: These drugs can accelerate the metabolism of active vitamin D metabolites in the liver and reduce the efficacy of the drug, so the dose of this drug should be appropriately increased. 5 Gastrointestinal absorption inhibitors: Cholestyramine or aluminum-containing antacids can reduce the absorption of this drug. The two should not be taken at the same time. The drugs should be taken one after the other with an interval of 2 hours. 6 Phosphorus agents: This product can induce hyperphosphatemia when used in combination with large doses of phosphorus agents.

Sealed storage

0.25 μg

24 months

Yaopharma Co., Ltd.

• Founded in:

  1997-07-21

• Address:

  No. 100, Xingguang Avenue, Renhe Town, Yubei District, Chongqing

• Tax NO.:

  91500000202851807X

• Registered Funds:

  196.54 million yuan

• Website:

  Log in to view

• Email:

  Log in to view